진행성 위암에 대한 1차 요법으로 Docetaxel과 Cisplatin 복합화학요법의 효과와 안정성에 대한 연구
Efficacy and safety of combination chemotherapy with docetaxel and cisplatin as a first-line treatment for advanced gastric cancer
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
본 연구에서는 수술 후 재발한 진행성 또는 절제 불가능한 전이성 위암을 가진 42명의 환자를 대상으로 1차 항암요법으로 docetaxel과 cisplatin을 투여하여 높은 반응률과 감내할만한 부작용을 확인할 수 있었다. 향후 많은 환자를 대상으로 한 전향적 연구와 표적치료제를 포함한 병용치료에 대한 연구가 필요할 것으로 판단된다.
Abstract
Background : To evaluate the activity and safety of docetaxel and cisplatin for advanced gastric cancer as a first-line chemotherapy treatment. Methods : Between December 2001 and February 2006, forty-two patients with recurrent or metastatic gastric cancer were enrolled. Docetaxel (75 mg/m2) was administered as a 1-hour intravenous infusion on day 1 and cisplatin (60 mg/m2) was also administered as a 30-minute intravenous infusion on day 1 every three weeks until disease progression or severe toxicity was detected. The response was assessed every 2 cycles. The toxicities were evaluated for every course of chemotherapy according to NCI toxicity criteria. Results : The median age of the patients was 66 (range, 33～77) years. Among the forty-two patients, 38 were male. Twenty-seven patients had an Eastern Cooperative Oncology Group performance score of 0 or 1 and fifteen patients had a score of 2. All patients had adenocarcinoma. Thirty-three of the forty-two patients were assessable for response. Partial responses were observed in 14 patients. The overall response rate was 42.4% (95% C.I., 25.259.6%) and the median response duration was 5.7 (range, 1.4～17.2) months. The median overall survival of all patients was 8.1 (range, 1.2～47.0) months. During a total of 170 cycles, granulocytopenia worse than National Cancer Institute toxicity grade 3 occurred in 7.6% of the patients, thrombocytopenia in 0.6% and anemia in 3.5%, respectively. No deaths resulting from toxicity were observed. Non-hematologic toxicities were minor and were easily controlled. Conclusion : Combination chemotherapy with docetaxel and cisplatin has a tolerable efficacy with acceptable toxicities in patients with advanced gastric cancer as a first-line treatment.(Korean J Med 72:593-599, 2007)
참고문헌 (20)
- Cocconi G, "Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer", Cancer Treat Rep, 66, pp.1263~1266 (1982)
- MacDonald JS, "5-fluorourcil, adriamycin and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer", Cancer, 44, pp.42~47 (1979)
- Haim N, "Further studies in the treatment of advanced gastric cancer by 5-fluorouracil, adriamycin and mitomycin (modified FAM)", Cancer, 54, pp.1999~2002 (1984)
- Cullinan SA, "Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer", J Clin Oncol, 12, pp.412~416 (1994)
- Kein HO, "Long-term results with FAMTX (5-f fluorouracil, adriamycin, metho- trexate) in advanced gastric cancer", Anticancer Res, 9, pp.1025~1026 (1989)
- Findlay M, "A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF)", Ann Oncol, 5, pp.609~616 (1994)
- Schoffski P, "New drugs for treatment of gastric cancer", Ann Oncol, 13(Suppl 4), pp.13~22 (2002)
- Murad AM, "Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer", Cancer, 72, pp.37~41 (1993)
- Glimelius B, "Initial or delayed chemotherapy with best supportive care in advanced gastric cancer", Ann Oncol, 5, pp.189~190 (1994)
- "Second International Conference on Biology, Prevention and Treatment of GI Malignancy", 1995, ~
- Pyhonen S, "Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer", Br J Cancer, 71, pp.587~591 (1995)
- Kim NK, "A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer", Cancer, 71, pp.3813~3818 (1993)
- Wils JA, "Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer", J Clin Oncol, 9, pp.827~831 (1991)
- Webb A, "Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer", J Clin Oncol, 15, pp.261~267 (1997)
- Vanhoefer U, "Final results of randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer", J Clin Oncol, 18, pp.2648~2657 (2000)
- Ohtsu A, "Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer", J Clin Oncol, 21, pp.54~59 (2003)
- Sulkes A, "Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trail", Br J Cancer, 70, pp.380~383 (1994)
- Roth AD, "Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma", Ann Oncol, 11, pp.301~306 (2000)
- Roth AD, "Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin- 5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK): 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)", J Clin Oncol, 22(Suppl), pp.4020~ (2004)
- Van Cutsem E, "Phase III study of odcetaxed and asplatin plus fluorouracil compased with asplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study Group", J Clin Oncol, 24, pp.4991~4997 (2007)